Device Trial Radar · NCT02922972
Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT
Last checked: Nov 19, 2026Latest source record: Nov 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Sep 2014
Primary completion
Sep 2017
Study completion Sep 2017
Sponsor
- Lead sponsor
- Regen Lab SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 4, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this prospective study is to assess the efficacy of autologous Platelet Rich Plasma prepared with RegenKit-BCT in the prevention and the treatment of keloid scars refractory to conventional treatments. Fifteen patients were included and received three PRP injection sessions with a one-month interval. The outcomes were assessed at baseline (before treatment), 3, 6, 12 and 24 months after the last injection session. Safety was assessed by reported adverse event analysis.
Conditions
- Keloid
Interventions
Autologous Platelet Rich Plasma obtained with RegenKit®-BCTDevice
After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients achieving a complete remission of their keloid scar 2 years after the end of treatment.Time frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.